SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.
Lutfi H AlfarsiRokaya El AnsariMadeleine L CrazeOmar J MohammedBrendah K MasisiIan O EllisEmad A RakhaAndrew R GreenPublished in: Breast cancer research and treatment (2021)
These findings suggest that metabolic alterations, particularly the interaction between the key amino acid transporter SLC1A5 and metabolic enzyme TALDO1, could affect the sensitivity of endocrine therapy. This study demonstrated the prognostic value of both SLC1A5 and TALDO1 as biomarkers in luminal breast cancer.